A comparison of anticholinergic burden in older patients with and without cancer.

Yasin A. I., Topcu A., Akuc M. N., Türk H. M., Soysal P.

Future oncology (London, England), cilt.17, sa.36, ss.5067-5075, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 36
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/fon-2021-0469
  • Dergi Adı: Future oncology (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.5067-5075
  • Anahtar Kelimeler: anticholinergic burden, cancer, elderly, geriatric assessment, geriatric oncology, polypharmacy, treatment, NEUROLEPTIC MALIGNANT SYNDROME, DRUG BURDEN, PHYSICAL FUNCTION, INDEX, MEDICATION, FALLS, HOSPITALIZATION, PRESCRIPTIONS, ASSOCIATIONS, DEPRESSION
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Lay abstract The elderly population is increasing rapidly worldwide, and most cancer patients are over the age of 65. In this age group, preexisting medical conditions other than cancer lead to the use of multiple drugs, which is defined as polypharmacy. Additionally, the anticholinergic burden (ACB) of the drugs affects cancer treatment in the elderly. This study investigated the frequency of polypharmacy and ACB in elderly patients with and without cancer and their relationship with geriatric syndromes such as depression, falls, nutritional and cognitive impairments. We found that ACB was higher in older patients without cancer than those with cancer and is related to increased falls, depressive symptoms, and impaired nutritional and functional status in older patients. Given the prevalence of cancer among older adults, it is crucial to understand the potential effects of the ACB for rational drug use and optimum cancer management in older patients with cancer.